GeneDx Holdings (WGS) EBT (2020 - 2026)

GeneDx Holdings (WGS) has reported EBT for 7 consecutive years, with -$18.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT fell 272.85% year-over-year to -$18.3 million in Q2 2026; TTM through Jun 2026 was -$106.3 million, a 7020.25% decrease from a year earlier, with the FY2025 full-year figure at -$21.1 million, up 59.84% from the prior year.
• EBT was -$18.3 million for Q2 2026 at GeneDx Holdings, up from -$62.4 million in the prior quarter.
• Over five years, EBT peaked at $10.6 million in Q2 2025 and troughed at -$308.7 million in Q4 2022.
• A 5-year average of -$51.6 million and a median of -$27.8 million in 2023 frame the typical range for EBT.
• Across the five-year window, EBT jumped 135.97% in 2025 and sank 926.29% in 2026, its largest moves.
• Over 5 years, EBT stood at -$308.7 million in 2022, then jumped by 91.52% to -$26.2 million in 2023, then jumped by 120.68% to $5.4 million in 2024, then sank by 436.72% to -$18.2 million in 2025, then dropped by 0.15% to -$18.3 million in 2026.
• The last three EBT figures came in at -$18.3 million (Q2 2026), -$62.4 million (Q1 2026), and -$18.2 million (Q4 2025), per Business Quant data.